Dmitry Balyasny’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,000
Closed -$582K 3257
2025
Q4
$582K Sell
1,000
-1,600
-62% -$817K ﹤0.01% 2458
2025
Q3
$1.19M Buy
+2,600
New +$970K ﹤0.01% 2043
2025
Q1
Sell
-1,300
Closed -$401K 3096
2024
Q4
$401K Sell
1,300
-8,900
-87% -$2.5M ﹤0.01% 2274
2024
Q3
$2.16M Buy
+10,200
New +$2.61M ﹤0.01% 1633

Other funds holding MDGL

Dmitry Balyasny's MDGL Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 79,011 shares worth $42.4M. The stake represents 0.05% of the portfolio and ranks #416 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in MDGL as recently as Q3 2025.

Dmitry Balyasny first reported a position in MDGL in Q4 2022 and has held it in 8 quarters since. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Dmitry Balyasny held 79,011 shares of Madrigal Pharmaceuticals worth $42.4M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Dmitry Balyasny position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.05% of Dmitry Balyasny's portfolio in Q2 2026, its #416 holding.
  • Dmitry Balyasny first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.